China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured RMB 150 million (USD 20.5 million) in a pre-Series C financing round. The investment, led by Guoxin Investment, includes participation from Gold Mine Multi-Family Office and Zheng Xiaodong, chairman of Shanghai Tofflon Sci &Tech Co., Ltd. This funding will be allocated towards advancing the company’s pipeline clinical trials and the commercialization of its innovative 3D printing technology in the pharmaceutical sector.
Funding History and Investors
Triastek has a robust track record of securing investments, having completed six financing rounds to date. The company’s list of backers includes notable names such as Tasly Group, Morningside Venture, Volcanics Venture, Dalton Venture, and Matrix Partners. This latest round of funding further solidifies Triastek’s position as a leader in the application of 3D printing technology for pharmaceutical development and manufacturing.
Innovative MED Drug 3D Printing Process
Triastek prides itself on its first-in-class melt extrusion deposition (MED) drug 3D printing process, a technology that has the potential to revolutionize the way drugs are developed and produced. The MED process offers advantages in precision, efficiency, and customization, which are critical factors in the pharmaceutical industry’s pursuit of innovation and quality.-Fineline Info & Tech
